Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Duodenal ulcer perforation07.04.02.0030.000087%Not Available
Duodenitis07.08.03.0010.000052%Not Available
Dysarthria19.19.03.001; 17.02.08.0010.000227%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000245%Not Available
Dysuria20.02.02.0020.000140%
Ear swelling04.03.01.0140.000052%Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000070%Not Available
Embolism venous24.01.01.0030.000052%Not Available
Encephalopathy17.13.02.0010.000192%
Enteritis07.08.03.0020.000035%
Enterocolitis haemorrhagic07.08.01.007; 24.07.02.0060.000035%Not Available
Eosinophilia01.02.04.0010.000140%
Eosinophilic pneumonia22.01.01.004; 01.02.04.0030.000035%Not Available
Erythema23.03.06.0010.000821%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000087%
Erythema nodosum23.07.02.001; 10.02.01.0200.000105%Not Available
Euphoric mood19.04.02.0060.000122%
Exophthalmos06.09.04.001; 05.02.02.0020.000035%Not Available
Exostosis15.02.04.0050.000035%
Extrasystoles02.03.02.0030.000070%Not Available
Eye disorder06.08.03.0010.000122%Not Available
Eye haemorrhage12.02.02.012; 24.07.05.002; 06.07.02.0010.000070%Not Available
Eye infection11.01.06.001; 06.04.05.007--
Eye inflammation06.04.05.0020.000087%Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.0020.000315%
Face oedema23.04.01.004; 08.01.07.003; 10.01.05.0020.000157%
Facial pain08.01.08.0120.000122%
Facial paralysis17.04.03.0080.000140%Not Available
Failure to thrive14.03.02.008; 19.07.05.001; 18.04.01.0030.000052%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene